Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTA 408 Lotion in Healthy Volunteers
NCT02029716Phase 1Completed
- Sponsor
- Biogen
- Start
- Dec 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of omaveloxolone in radiation dermatitis (3 arms), sponsored by Biogen. Primary endpoint: Skin changes or redness following topical application at 14 days. Started Dec 2013; status: completed.
02
Drugs
omaveloxolone
03
Conditions
radiation dermatitis
Beyond the preview
Go deeper on NCT02029716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029716.